Eye-Strengthening light therapy tested to halt blinding cornea disease

NCT ID NCT01604135

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a procedure called corneal collagen crosslinking for people with progressive keratoconus, a condition where the cornea thins and bulges, blurring vision. The treatment uses riboflavin (vitamin B2) drops and UV light to stiffen the cornea. The study aims to see if it can stop the cornea from getting steeper over 12 months, potentially preventing the need for a cornea transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
corneal collagen crosslinking (a procedure using riboflavin drops and UV light to strengthen the cornea)
What this could lead to
If it works, this could offer a way to halt keratoconus progression and avoid the need for a cornea transplant.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The procedure may not stop progression in all cases, and there are risks like infection or corneal haze.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KERATOCONUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Ophthalmology, Sahlgrenska University Hospital

    Mölndal, Västra Götalandsregionen, 43180, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.